Published in Medical Devices and Surgical Technology Week, October 17th, 2004
IUdR is "an effective radiosensitizer but its clinical development has been limited by toxicity," oncologists in England explained. "Prolonged intravenous infusions of IUdR are necessary for optimal tumor uptake but cause dose-limiting myelosuppression."
"The lack of selective tumor uptake can lead to radiosensitization of adjacent normal tissues and enhanced local radiation toxicity," stated K.J. Harrington and colleagues at the Institute of Cancer Research in London. "Liposomal IUdR delivery offers selective targeting of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.